<DOC>
	<DOCNO>NCT03046901</DOCNO>
	<brief_summary>The purpose study investigate safety efficacy oral vancomycin patient recurrent Primary Sclerosing Cholangitis ( PSC ) liver transplantation . The primary endpoint look effect drug liver function test , important surrogate PSC disease activity 12 week treatment . Secondary endpoint include decrease liver function test 1 year , change bilirubin adverse event . Effective treatment onset PSC recurrence may lead decrease disease progression , recurrent liver failure , repeat liver transplantation .</brief_summary>
	<brief_title>Vancomycin Treatment Recurrent PSC Liver Transplant Patients</brief_title>
	<detailed_description />
	<mesh_term>Cholangitis</mesh_term>
	<mesh_term>Cholangitis , Sclerosing</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<criteria>1 . History prior orthotopic liver transplant liver kidney transplant . 2 . Recurrent PSC confirm clinical lab ( AST/ALT great 19 ALKP great normal ) , image ( MRCP ERCP ) , and/or liver biopsy consistent recurrent PSC . 3 . No clinical evidence liver transplant rejection stability posttransplant immune suppression dose three month prior enrollment study 4 . No change therapy inflammatory bowel disease least three month prior enrollment ( patient history IBD ) 5 . Patients ursodiol must stable dose two week prior enrollment dose must stable remainder clinical trial . 6 . All patient inflammatory bowel disease must colonoscopy within year prior enrollment 7 . No antibiotic 2 month start vancomycin 8 . No probiotic 1 month prior start vancomycin study period Exclusion Criteria 1 . Allergy vancomycin 2 . Preexisting advanced malignancy 3 . Pregnancy Lactation 4 . Inability provide consent 5 . Findings suggestive liver disease etiology chronic alcoholic liver disease , chronic hepatitis B C infection , autoimmune hepatitis , primary biliary cirrhosis , hemochromatosis , Wilson 's disease , congenital biliary disease . 6 . Current biliary obstruction 7 . Active infection 8 . Involvement investigational study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Vancomycin</keyword>
	<keyword>Primary Sclerosing cholangitis</keyword>
	<keyword>Post-liver transplantation</keyword>
</DOC>